Accelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research report report published on Wednesday morning. The brokerage issued a hold rating on the medical research company’s stock.

Accelerate Diagnostics Stock Performance

AXDX opened at $1.31 on Wednesday. Accelerate Diagnostics has a 1 year low of $0.73 and a 1 year high of $4.99. The firm has a 50 day moving average price of $1.76 and a 200 day moving average price of $1.55. The company has a market cap of $32.80 million, a PE ratio of -0.46 and a beta of 0.56.

Insider Buying and Selling at Accelerate Diagnostics

In related news, Director John Patience purchased 200,000 shares of Accelerate Diagnostics stock in a transaction dated Tuesday, December 3rd. The shares were acquired at an average price of $1.57 per share, with a total value of $314,000.00. Following the completion of the transaction, the director now owns 653,224 shares of the company’s stock, valued at approximately $1,025,561.68. This trade represents a 44.13 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 43.60% of the stock is owned by insiders.

Institutional Trading of Accelerate Diagnostics

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the third quarter, according to its most recent filing with the SEC. The fund purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned about 0.08% of Accelerate Diagnostics at the end of the most recent quarter. Institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.